Nuvalent, Inc.
NUVL
Rank in Stocks
#2101
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Share Price
$123.96
Last synced: 2026-07-21
Market Cap
$9.75B
Change (1 day)
0.00%
Change (1 year)
33.98%
Country
US
Trade Nuvalent, Inc. (NUVL)
Category
Healthcare
Dividend history for Nuvalent, Inc. (NUVL)
Nuvalent, Inc. (stock symbol: NUVL) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Nuvalent, Inc. (NUVL) from 2026 to 2026
Annual dividend payments
| Year | Dividend (stock split adjusted) | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
List of all dividend payments
| Year | Dividend | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Dividend payments for similar companies or competitors
| Company | Number of dividend payments | Country |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
